Kovitz Investment Group Partners
NVCR icon

Kovitz Investment Group Partners’s NovoCure NVCR Stock Holding History

Kovitz Investment Group Partners’s Portfolio NVCR Stock Details NVCR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-19,574
Closed -$253K – 1034
2025
Q3 		$253K Buy
+19,574
New +$262K ﹤0.01% 1258

Other funds holding NVCR

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.47B AUM 115.63% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
QCM
Quantinno Capital Management New York $59.9B AUM 28.07% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return

Kovitz Investment Group Partners's NVCR Position: Q4 2025 in Review

Kovitz Investment Group Partners sold out of NovoCure (NVCR) in Q4 2025, closing a stake of 19,574 shares — an estimated $253K sold.

Kovitz Investment Group Partners first reported a position in NVCR in Q3 2025 and held it in 1 quarter. The position peaked at $253K in Q3 2025. 238 funds tracked by Wall St. Rank hold NVCR as of Q4 2025.

  • Kovitz Investment Group Partners reported no remaining NovoCure position as of Q4 2025 after selling out during the quarter.
  • Kovitz Investment Group Partners sold 19,574 NovoCure shares in Q4 2025, an estimated $253K.
  • Kovitz Investment Group Partners first reported a position in NovoCure in Q3 2025 and held it in 1 quarter.
  • Kovitz Investment Group Partners's NovoCure position peaked at $253K in Q3 2025.
  • 238 funds tracked by Wall St. Rank held NovoCure as of Q4 2025.

Based on Kovitz Investment Group Partners's 13F filing for Q4 2025, filed 20 Feb 2026.